Could fat hold the key to finally treating Parkinson’s disease? A study by researchers at Harvard Medical School and Massachusetts General Hospital has suggested that fatty tissue could produce a source of homegrown stem cells needed to create long-sought-after regenerative treatments for a range of central nervous system disorders.
These neural stem cells were first identified while scientists were examining subcutaneous adipose tissue (SAT), otherwise known as body fat, in mice and noticed that a clump of nerve fibers included what appeared to be Schwann cells, a type of cell involved in the maintenance and regeneration of the motor and sensory neurons of the peripheral nervous system. Further in vitro analysis of these Schwann cells showed they can develop stem-cell-like qualities, according to a study published May 25 in Science Translational Medicine.
The researchers noted that when the cells were grafted into the gastrointestinal tracts of mice, they differentiated into both neurons and supportive glial cells, which provide physical and metabolic support to neurons. What’s more, the Schwann cells were shown to have regenerative properties, improving digestive function in mice with digestive disorders like gastroparesis and colonic aganglionosis.
But their potential benefits don’t stop at the stomach—the researchers pointed out that the main barrier to developing effective treatments for the likes of Parkinson’s and stroke has been sourcing neural stem cells from the patient’s own body.
“Because adipose stem cells are widely considered to be safe therapeutic agents for humans … the derivation of SAT-[neural stem cells] offers unprecedented potential for therapeutic application in neurological diseases,” the researchers said.
Before that, more work is required to define the properties of these cells and establish protocols to isolate and expand them, they added.
By Max Bayer, James Waldron
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.